Table 1 Baseline characteristics of Behcet’s disease (N = 117)
Variables | CHIP( +) (n = 13) | CHIP( −) (n = 104) | *p value |
|---|---|---|---|
Age at blood sampling (years) | 58.1 ± 11.4 | 45.1 ± 13.3 | 0.001 |
Disease duration (years) | 6.6 ± 4.1 | 7.6 ± 5.9 | 0.540 |
Sex (male) | 8 (61.5%) | 48 (46.2%) | 0.381 |
Body mass index (kg/m2) | 21.1 ± 3.0 | 21.8 ± 3.4 | 0.507 |
Smoking history | 4 (30.8%) | 29 (27.9%) | 1.000 |
Symptom of BD | |||
Oral ulcer | 5 (38.5%) | 57 (54.8%) | 0.378 |
Genital ulcer | 1 (7.7%) | 26 (25.%) | 0.263 |
Eye manifestation | 1 (7.7%) | 8 (7.7%) | 1.000 |
Skin manifestation | 1 (7.7%) | 38 (36.5%) | 0.058 |
Arthritis | 4 (30.8%) | 25 (24.0%) | 0.734 |
Vascular manifestation | 1 (7.7%) | 3 (2.9%) | 0.380 |
Central nervous system manifestation | 0 (0.0%) | 1 (1.0%) | 1.000 |
Intestinal BD | 12 (92.3%) | 78 (75.0%) | 0.294 |
Previous medication | |||
5-ASA | 12 (92.3%) | 75 (72.1%) | 0.179 |
Corticosteroid | 6 (46.2%) | 71 (68.3%) | 0.130 |
Immunomodulator | 7 (53.8%) | 55 (52.9%) | 1.000 |
Anti-TNF | 2 (15.4%) | 20 (19.2%) | 1.000 |
Current medication | |||
Immunomodulator | 3 (23.1%) | 28 (26.9%) | 0.698 |
Anti-TNF | 0 (0.0%) | 17 (16.3%) | 0.029 |
Laboratory findings at diagnosis | |||
WBC count (/µL) | 8511.5 ± 3510.8 | 7677.3 ± 2927.6 | 0.345 |
Neutrophil count (/µL) | 5601.6 ± 2586.5 | 5064.6 ± 2748.2 | 0.506 |
Lymphocyte count (/µL) | 2024.3 ± 1108.3 | 1873.8 ± 832.4 | 0.556 |
Haemoglobin (g/dL) | 12.0 ± 1.9 | 12.7 ± 1.8 | 0.210 |
Platelet count (/µL) | 369,000.0 ± 176,870.9 | 283,000.0 ± 77,279.8 | 0.002 |
NLR ratio | 3.92 ± 3.96 | 3.82 ± 4.78 | 0.939 |
PLR ratio | 259.8 ± 220.6 | 205.8 ± 190.3 | 0.785 |
ESR (mm/h) | 69.5 ± 42.5 | 36.6 ± 29.8 | 0.001 |
CRP (mg/L) | 30.5 ± 40.2 | 12.9 ± 28.0 | 0.046 |
Albumin (g/dL) | 3.9 ± 0.4 | 4.2 ± 0.4 | 0.027 |
Clinical outcomes | |||
Medical acceleration (events) | 7 (53.8%) | 58 (56.3%) | 1.000 |
Surgery (events) | 4 (30.8%) | 19 (18.3%) | 0.282 |
Emergency room visit (events) | 5 (38.5%) | 32 (30.8%) | 0.546 |
Hospitalisation (events) | 6 (46.2%) | 43 (41.3%) | 0.772 |